Eagle’s Eye View: Your Weekly CV Update from ACC.org (Week of Sept. 5)

In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss a prespecified analysis of the DELIVER Trial that investigated the efficacy and safety of dapagliflozin according to frailty in patients with heart failure, then looks at a separate paper on the DELIVER Trial that examines dapagliflozin for heart failure according to body mass index. Finally, Dr. Bhatt examines a prospective cohort study of UK Biobank participants that looked at the association between device-measured physical activity and incident heart failure.

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure, Prevention

Keywords: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Spironolactone, Ventricular Function, Left, EaglesEyeView

< Back to Listings